Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
1.49
Nov 17 • 3:59 PM ET Dollar change-0.11 Percentage change(-6.88%)
Aftermarket Close
1.46
Aftermarket • 7:30 PM ET Dollar change-0.03 Percentage change(-2.01%)
Index
RUT
Market Cap
146.42M
Enterprise Value
-45.76M
Income
-141.67M
Sales
0.00M
Book/sh
2.09
Cash/sh
2.33
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
106
IPO
Apr 03, 2020
P/E
-
Forward P/E
-
PEG
-
P/S
-
P/B
0.71
P/C
0.64
P/FCF
-
EV/EBITDA
-
EV/Sales
-
Quick Ratio
7.33
Current Ratio
7.33
Debt/Eq
0.18
LT Debt/Eq
0.16
Option/Short
Yes / Yes
EPS (ttm)
-1.93
EPS next Y
-1.66
EPS next Q
-0.40
EPS this Y
5.40%
EPS next Y
7.96%
EPS next 5Y
9.21%
EPS past 3/5Y
24.78% 7.86%
Sales past 3/5Y
- -
EPS Y/Y TTM
7.45%
Sales Y/Y TTM
-100.00%
EPS Q/Q
7.95%
Sales Q/Q
-
Insider Own
29.14%
Insider Trans
17.84%
Inst Own
55.81%
Inst Trans
4.09%
ROA
-47.43%
ROE
-61.90%
ROIC
-59.69%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
SMA20
-21.08%
SMA50
-38.77%
SMA200
-56.02%
Trades
Shs Outstand
98.26M
Shs Float
69.63M
52W High
6.95 -78.56%
52W Low
1.28 16.41%
Volatility
12.81% 9.70%
ATR (14)
0.19
RSI (14)
26.69
Beta
1.95
Rel Volume
1.03
Avg Volume
1.26M
Volume
1,296,095
Perf Week
-17.22%
Perf Month
-35.22%
Perf Quarter
-60.99%
Perf Half Y
-57.91%
Perf YTD
10.37%
Perf Year
12.88%
Perf 3Y
-86.87%
Perf 5Y
-98.12%
Perf 10Y
-
Prev Close
1.60
Price
1.49
Change %
-6.88%
Consensus
Strong Buy
Avg. Price Target
$7.80
Implied Upside
+423.5%
Analysts11incl. previous ratings
Rating Distribution7 Buy · 4 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Nov 10, 2026Upgrade
WWedbush
Neutral → Outperform$6+302.7%
Nov 10, 2026Upgrade
WWedbush
Neutral → Outperform$5 → $6+302.7%
Oct 05, 2026Resumed
LLeerink Partners
Outperform$8+436.9%
Sep 30, 2026Resumed
WFC logoWWells Fargo
Equal Weight$5+235.6%
Sep 16, 2026Initiated
WWilliam Blair
Outperform
Jul 23, 2026Initiated
RRodman & Renshaw
Buy$11+638.3%
Jul 17, 2026Initiated
MFG logoMMizuho
Outperform$8+436.9%
Mar 17, 2026Resumed
WFC logoWWells Fargo
Equal Weight$5+235.6%
Aug 12, 2024Upgrade
WWedbush
Underperform → Neutral$4+168.5%
Jun 20, 2024Downgrade
UBS logoUUBS
Buy → Neutral$28 → $5+235.6%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
WALTERS GROUP10% OwnerAug 14 '26Buy3.504,335,00015,172,50017,844,973Aug 19 06:11 PM
Bruns IngmarChief Medical OfficerFeb 06 '26Sale2.432,9627,19733,667Feb 10 09:10 PM
Bruns IngmarChief Medical OfficerFeb 09 '26Sale2.3933580233,332Feb 10 09:10 PM
Vultaggio VincentPAO and PFOFeb 06 '26Sale2.4329,95172,772156,779Feb 10 09:10 PM
Vultaggio VincentPAO and PFOFeb 10 '26Sale2.426,89416,699146,506Feb 10 09:10 PM
Vultaggio VincentPAO and PFOFeb 09 '26Sale2.393,3798,086153,400Feb 10 09:10 PM
EASTLAND JULIA MARIECEO & PresidentFeb 06 '26Sale2.437,86619,11280,022Feb 10 09:09 PM
EASTLAND JULIA MARIECEO & PresidentFeb 09 '26Sale2.398892,12779,133Feb 10 09:09 PM
Vultaggio VincentPAO and PFOFeb 02 '26Sale2.552,5406,477187,286Feb 04 08:27 PM
Vultaggio VincentPAO and PFOFeb 03 '26Sale2.525561,398186,730Feb 04 08:27 PM
WALTERS GROUP10% OwnerDec 31 '25Buy1.206,459,9737,751,96813,509,973Jan 08 04:57 PM
Matrix Capital Management Comp10% OwnerDec 15 '25Sale1.337,500,0009,975,0006,459,973Dec 15 05:24 PM
Zentalis Pharmaceuticals, Inc. is a clinical oncology innovator developing an oral, non-chemotherapy, biomarker-driven treatment approach for ovarian cancer and multiple tumor types. The therapeutics development and biomarker expertise is advancing monotherapy and combination studies of its investigational potential first-in-class WEE1 inhibitor, azenosertib. It is focused on translating WEE1 science into clinical practice, aiming to equip physicians with a targeted, orally available medicine that enhances treatment experience, choice, and outcomes. The company was founded by Kevin D. Bunker and Cam Gallagher on December 23, 2014 and is headquartered in San Diego, CA.
CEOMs. Julie M. Eastland M.B.A.
Chief Legal Officer & Corporate SecretaryMr. James B. Bucher J.D.
Ph.D.Dr. Ingmar Bruns M.D.
SVP of Finance & Principal Accounting OfficerMr. Vincent A. Vultaggio
Chief Technical OfficerMr. Robert J. DiVasto P.E.